Eugia Pharma

Profile data last refreshed 2w ago

Open Jobs

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

0 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Products & Portfolio (5)

1 discontinued, 0 duplicate formulations not shown

DEXMEDETOMIDINE HYDROCHLORIDE

dexmedetomidine hydrochloride in 0.9% sodium chloride

Post-LOE

INJECTION · INJECTABLE

2 -adrenergic agonist with sedative properties. Alpha 2 selectivity is observed in animals following slow intravenous infusion of low and medium doses (10 to 300 mcg/kg). Both alpha 1 and alpha 2 activity is observed following slow intravenous infusion of high doses (≥1,000 mcg/kg) or with rapid intravenous administration.

Help build intelligence for Eugia Pharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Eugia Pharma

Products & Portfolio (5)

Open Jobs (0)